On September 28, 2022, the U.S. Food and Drug Administration
(“FDA” or “the Agency”) issued its
long-awaited final guidance, “Clinical Decision Support
Software” (the “CDS Guidance”). The CDS Guidance
follows the Agency's September 2019 draft guidance of the
same name (the “Draft Guidance”) and seeks to clarify
several key concepts for determining whether clinical decision
support (“CDS”) software is a medical device.
Specifically, the CDS Guidance provides the Agency's
interpretation of the four criteria established by the 21st Century
Cures Act for determining whether a decision support software
function is excluded from the definition of a device (i.e., is
considered “Non-Device CDS”). A software function must
meet all of the following four criteria to be considered Non-Device
CDS: